Opendata, web and dolomites

ANAPRINT

Additive Printing for Cell-based Analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ANAPRINT project word cloud

Explore the words cloud of the ANAPRINT project. It provides you a very rough idea of what is the project "ANAPRINT" about.

producing    screening    healthcare    leaders    skills    post    launch    arising    efficiencies    human    ranging    positive    ip    assay    strategic    beta    data    national    core    asia    confidence    platform    reactive    functional    competitive    initial    japan    whilst    extend    trl7    distributors    12    uk    client    specialist    sold    marketed    partnership    commercial    manufacturing    operations    expanding    se    assays    budget    volume    6m       printed    innovation    materials    printing    financial    ready    integration    advantage    aided    market    plan    hepatocytes    jv    prototype    companies    hepatotoxicity    predictive    multiple    planning    industry    assembly    prototypes    automating    win    successful    acs    drugs    scalable    alone    sales    additive    commercialise    cagr    2bn    sectors    audit    global       2016    remote    centre    15    culture    disruptive    opinion    business    party    services    trl9    moved    5m    ipsc    models    share    pricing    extension    decisions    cell    consistent    markets    foods    forecast   

Project "ANAPRINT" data sheet

The following table provides information about the project.

Coordinator
AvantiCell Science Ltd 

Organization address
address: GIBBSYARD BUILDING
city: AYR
postcode: KA6 5HW
website: www.avanticell.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.avanticell.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2015-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AvantiCell Science Ltd UK (AYR) coordinator 50˙000.00

Map

 Project objective

The Project will develop and commercialise the additive printing of cell-based analysis systems. The objective is to deliver consistent, scalable manufacturing of cell-based models used by multiple industry sectors to evaluate materials ranging from new drugs to healthcare products and functional foods. The target market is global and growing (CAGR 12%; estimated $4.2Bn in 2016). Additive printing will have positive disruptive impact, automating assay assembly and producing complex models needed by industry to improve the predictive value of cell-based analysis. Operational efficiencies and competitive pricing of printed cell products and services will win market share by making high-end analysis available to non-specialist users, whilst allowing wider integration of complex models into high-volume screening. The market advantage will be cost-effective testing and greater confidence in commercial decisions with strategic and financial impact. The Phase 1 business plan will be built on market data, IP/technology audit and financial planning arising from 8 years’ successful ACS cell-based business. Phase 1 shall also prototype assays printed with iPSC-derived hepatocytes aimed at high-value hepatotoxicity testing; prototypes will be moved to TRL7, and in Phase 2 to market-ready TRL9 with client-reactive design aided by beta testing with opinion leaders. Technical innovation will use ACS core skills in human cell culture and build on commercial partnership with the UK National Centre for Additive Printing. Phase 2 will extend the technology platform to other cell models, expanding product range and commercial value. Post-project, these will be marketed and sold by expanding existing operations: initial hepatotoxicity sales alone are forecast at €0.6M one year post-launch (0.15% of global market). Market/sales extension to remote markets e.g. SE Asia will use JV companies or third-party distributors e.g. Japan. The Project requires 2.5 years and a budget of €2-2.5M.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANAPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANAPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

INFINITE (2015)

INnovative laser machine For INdustrial engravIng and 3d TExturing

Read More  

FREE-D (2015)

CNC dynamic mold for producing freely curved glass panels

Read More  

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More